Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.42 USD | +0.74% | +4.03% | -39.71% |
Financials (USD)
Sales 2024 * | 227M | Sales 2025 * | 282M | Capitalization | 773M |
---|---|---|---|---|---|
Net income 2024 * | 9M | Net income 2025 * | 71M | EV / Sales 2024 * | 1.66 x |
Net cash position 2024 * | 395M | Net cash position 2025 * | 448M | EV / Sales 2025 * | 1.15 x |
P/E ratio 2024 * |
93.4
x | P/E ratio 2025 * |
11.5
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.93% |
Latest transcript on Aurinia Pharmaceuticals Inc.
1 day | +0.74% | ||
1 week | +4.03% | ||
1 month | +4.23% | ||
3 months | -6.23% | ||
6 months | -40.18% | ||
Current year | -39.71% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | -.--% | - | |
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 5.42 | +0.74% | 1,619,070 |
24-05-30 | 5.38 | +4.26% | 898,615 |
24-05-29 | 5.16 | -2.46% | 902,387 |
24-05-28 | 5.29 | +1.54% | 819,406 |
24-05-24 | 5.21 | -0.57% | 681,996 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.71% | 773M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- AUPH Stock